April 8, 2020
U.S. Supreme Court Upholds Nitric Oxide Patent Win for Linde; Linde Commits to Support Inhaled Nitric Oxide Clinical Studies Relating to COVID-19
Guildford, UK, April 8, 2020 - Linde (NYSE:LIN; FWB:LIN), a leading global supplier of inhaled nitric oxide, is pleased with the decision by the U.S. Supreme Court declining to review the 2019 appeals court decision that affirmed Praxair Distribution, Inc.'s (PDI) right to sell a generic form of inhaled nitric oxide. This decision ends the long-running U.S. patent litigation with Mallinckrodt plc, and affirms the ability of PDI, a wholly owned subsidiary of Linde, to continue supplying inhaled nitric oxide. This drug product is widely used as approved in the U.S. and other countries to improve oxygenation of certain groups of patients.
Business News